Indications for: VEKLURY
COVID-19 in patients requiring hospitalization.
Give by IV infusion over 30–120mins. ≥12yrs (≥40kg): Initially 200mg once on Day 1, followed by 100mg once daily from Day 2. Patients not requiring invasive mechanical ventilation and/or extracorporeal membrane oxygenation (ECMO): treat for 5 days; if no improvement, may extend for a total duration of 10 days. Patients requiring invasive mechanical ventilation and/or ECMO: treat for 10 days.
<12yrs or <40kg: not established.
Should only be administered in a hospital or in a healthcare setting providing acute care. Obtain eGFR, hepatic tests, and prothrombin time prior to initiation and monitor during treatment. Consider discontinuing if ALT levels increase to >10×ULN. Discontinue if ALT elevation is accompanied by signs/symptoms of liver inflammation. Monitor closely for hypersensitivity reactions during and following therapy; discontinue immediately if significant reactions occur. Renal impairment (eGFR <30mL/min): not recommended. Hepatic impairment. Elderly (monitor). Pregnancy. Nursing mothers.
SARS-CoV-2 nucleotide analogue RNA polymerase inhibitor.
Do not administer the diluted solution simultaneously with any other medication. Concomitant chloroquine phosphate or hydroxychloroquine sulfate: not recommended.
Nausea, increased ALT/AST; hypersensitivity reactions, generalized seizure, rash.
Generic Drug Availability: